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a b s t r a c t
Leprosy is a chronic infectious disease caused by Mycobacterium leprae. It is known for its
great disﬁguring capacity and is considered an extremely serious disease to public health
worldwide. The state of Ceará ranks 13th in number of cases of leprosy in Brazil, and fourth
in Northeastern region, with an average of 2,149 new cases diagnosed every year. This study
aimed to evaluate the knowledge of leprosy patients regarding treatment, and to assess
the level of treatment adherence and its possible barriers. The study was conducted in
the reference center for dermatology, from September 2010 to October 2010, in Fortaleza,
Ceará. The study data were collected by means of a structured interview, along with the
Morisky-Green test, in order to assess treatment adherence and barriers to adherence. A
total of 70 patients were interviewed, out of whom 66 were new cases. The majority of
patients were between 42 and 50 years old, and 37 (52.9%) were male. Most patients were
clinically classiﬁed as presenting multibacillary leprosy (80%), and 78.6% of them were from
Fortaleza, Brazil. The Morisky-Green test indicated that 62.9% of patients presented a low
level of adherence (p<0.005), despite claiming to aware of the disease risks. However, it was
observed that 57.1% of the patients had no difﬁculty adhering to treatment, while 38.6%
reported little difﬁculty. This study shows that despite the patients claiming to be familiarwith leprosy and its treatment, the Morisky-Green test clearly demonstrated that they actu-
ally were not aware of the principles of therapy, which is evidenced by the low degree of
treatment adherence.
lic health, both in Brazil and in the world. In 2010, a total
© 2012 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDLeprosy is a chronic contagious infectious disease caused
by Mycobacterium leprae, an intracellular bacterium that has
afﬁnity for both skin cells and Schwann cells of peripheral
nerve tissues. This microorganism is acquired through the
respiratory route. Clinical manifestations only appear years
after the ﬁrst contact with the bacillus.1
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Este é um artigo Open Access sob a licençaLeprosy is a reportable disease known for its disﬁguring
capacity. It is considered an extremely serious disease to pub-
2eza, CE, 60425-480, Brazil.
of 211,903 cases of leprosy were reported to the World Health
Organization (WHO) from 141 countries or territories.3 Brazil
presents high incidence rates of leprosy, and the Northeast
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Table 1 – Patient characteristics according to the level of
knowledge and difﬁculties to adhere with treatment.
Variable n %
Knew about the disease before
diagnosis
Yes 37 52.9
No 33 47.1
Researched to learn more about
the disease after diagnosis
Yes 43 61.4
No 27 38.6
Knowledge of the medications used
Yes 7 10.0
No 63 90.0
Knowledge of how many
medications were used
Yes 67 95.7
No 3 4.3
Knowledge regarding treatment
duration
Yes 52 74.3
No 18 25.7
Difﬁculties for treatment
No complaint 21 30
Bias 4 5.7
Displacement 8 11.4
Reaction to medication 18 25.7
Delay in treatment 16 22.9braz j infect d i s .
egion is the most affected. The disease is endemic in the
tate of Ceará, presenting high incidence rates.2 In 2010, Ceará
eached a detection rate of 25.4 for every 100,000 inhabi-
ants; it ranks 13th among the states in Brazil and the 4th
n the Northeast Region, with an average of 2,149 new cases
nnually.4
Despite the myths about this ancient disease, its treatment
s possible, especially if a diagnosis is correctly established
t early stages of the disease, following the polychemother-
peutic regimen recommended by the Brazilian Ministry of
ealth and standardized by the WHO. Therapy includes drugs
uch as dapsone, rifampicin, and clofazimine, among oth-
rs. These drugs are provided by the WHO without charge.
owever, Brazil remains the second country in the world in
umber of cases of leprosy, despite all efforts to eradicate
his disease. In addition, Brazil is the most affected coun-
ry in South America, accounting for 80% of all reported
ases.5
Two major challenges must be overcome in order to reduce
eprosy prevalence. The ﬁrst challenge is the long duration of
reatment, which depends on clinical features, varying from
ix months to one year.1 The second challenge are the inﬂam-
atory and hypersensitivity reactions during treatment, due
o M. leprae antigen release.
After starting the appropriate therapy, patients no longer
ransmit thedisease.However, because of the challengesmen-
ioned above, therapy is frequently abandoned, which leads to
isease dissemination, considering that treatment adherence
s closely related to disease control.6 Thus, this study aimed
o evaluate the knowledge of leprosy patients about the treat-
ent, and to detect the level of treatment adherence and its
ossible difﬁculties.
An exploratory-descriptive quantitative survey was carried
ut in this study. The research was conducted at the Cen-
ro de Referência Nacional em Dermatologia Sanitária Dona
ibânia, from September to October 2010, Fortaleza, Ceará,
nd approved by the Ethics Committee of the center (protocol
umber 031/2010).
The sample consisted of 70 patients with conﬁrmed diag-
osis of leprosy. Patients on treatment or not, BCG vaccinated
r not (presence of vaccine scar) were included; patients under
8 years of age, those who had completed treatment, or those
ithout a conﬁrmed diagnosis were excluded. In order to
articipate in this survey, patients had to sign an informed
onsent; their anonymity was preserved.
This study used a structured questionnaire ascertaining
ocioeconomic characteristics of the subjects, such as age,
ender, education level, and questions concerning individual
nowledge about the disease. To assess the level of treat-
ent adherence, the Morisky-Green test,7 which consists of
our yes/no questions, was used. Positive answers scored no
oints, while each negative answer represented one point.
hen all questions were answered negatively, a maximum
f four points was obtained, which indicated high degree of
dherence; a single positive answer was sufﬁcient to indicate
ow treatment adherence.The degree of difﬁculty to adhere with treatment was also
ssessed.8 This comprised 10 adherence-relatedquestions, for
hich responses were given on a scale: totally agree, partially
gree, undecided, partially disagree, and strongly disagree,Change of routine 3 4.3
with values varying from 5 to 1, respectively. The results were
interpreted by the Likert scale: 10 to 20 points represented no
difﬁculty in adhering with treatment; 21 to 30, little difﬁculty;
31 to 40, moderate difﬁculty; and 41 to 50, great difﬁculty in
adhering with treatment. Data were evaluated through Pear-
son’s chi-squared test. For the univariate analysis, a binomial
test was used to analyze the equality of proportions when
there were only two categories of variables; when there were
more than two categories, the multinomial test was used. The
Statistical Package for Social Sciences (SPSS 15.1 for Windows)
was used for data analysis. Absolute and relative frequencies
were used for clinical characterization of patients, and the
chi-squared test was used to assess correlations.
The socioeconomic and clinical proﬁle of the patients
showed that 52.9% of patients were male and 47.1% were
female. In relation to marital status, 44.3% were single, 50%
married, and 5.7% widowed. Most patients lived in Fortaleza,
while 24.1% lived in the countryside of the state of Ceara. Con-
cerning the number of inhabitants in their households, 45.7%
declared to live with one to three people, and 42.9% declared
to live with four to six other people. Regarding the educational
level, 45.7% had completed middle school.
Most patients (80%) presented multibacillary leprosy, while
20.0%presented thepaucibacillary type. In relation toBCGvac-
cination, it was observed that 49 studied patients (70%) had
a vaccination scar. Additionally, 94.3% of patients were new
cases undergoing treatment for the ﬁrst time.
Table 1 demonstrates the patients’ knowledge of the
disease before being medically assisted and knowledge of
i s . 20474 braz j infect d
treatment. It was observed that 52.9% had heard about the
disease at diagnosis, and 61.4% had searched for more infor-
mation about leprosy. However, 90% of the patients did not
know which medications they had used, but 95.7% were aware
of howmany different drugs theywere taking, and 74.3% knew
the duration of therapy. Of all patients, 30% had no complaints
about the treatment, but 27.5% had complained of drug reac-
tions and 22.9% of treatment length.
Regarding the Morisky-Green test, 62.9% of patients pre-
sented low level adherence, while 37.1% were classiﬁed
as patients with high adherence rate (p<0.005). Finally,
regarding the degree of difﬁculty in adhering with treat-
ment, it was found that 57.1% of patients had no difﬁculty,
38.6% had little difﬁculty, and only 4.3% had moderate
difﬁculty.
Data obtained with the Morisky-Green test was compared
with the following variables: “researched to learn more about
the disease after diagnosis”, “knowledge of treatment dura-
tion”, and “knowledge of which drugs they were using”. In the
association between the Morisky-Green test and the variable
“researched to learn more about the disease after diagnosis”„
even though they Despite being in the low level adherence
group (n=44), 27 patients (61%) researched to learnmore about
the disease. Similarly, 16 (62%) patients in the high-adherence
group (n=26) also researched to learn more about leprosy.
Regarding the variable “knowledge of treatment duration”,
80% of low adherence patients knew the duration of treat-
ment, while 65% of high adherence patients were aware about
treatment duration. Finally, 14% (n=6) of the low adherence
patients knew the name of the medications and only one
patient (4%) out of the 26 high adherence patients claimed
to know the name of the medications.
The association between the degree of difﬁculty in adher-
ing with treatment and the variable “researched to learn more
about the disease after diagnosis”, 26 (59%) out of 44 patients
who had no difﬁculty in adhering with treatment claimed to
have researched to learn more about the disease. Out of the 24
patientswith little difﬁculty, 15 (63%) reported the same,while
100% (n=2) of the patients categorized as havingmoderate dif-
ﬁculty in treatment adherence said to have researched more
information on the disease.
Concerning the variable “knowledge of treatment dura-
tion”, 73% of patients who had no difﬁculty in adhering with
treatment were aware of the treatment duration, as well as
79%of thosewhohad little difﬁculty, and50%of thosewhohad
moderate difﬁculty. Finally, concerning the variable “knowl-
edge of the name of the drugs they are using”, out of the
44 patients who presented no difﬁculty in adhering treat-
ment, 91% (n=40) knew the name of the medications. 88%
of patients who had little difﬁculty also knew the name of the
medications and so did the two (100%) patients who reported
moderate difﬁculty.
Leprosy remains a serious public health problem world-
wide, despite the mobilization of several health agencies
attempting to eradicate this disease. Thus, it is necessary
to do more research regarding not only the epidemiological
aspects, but also the obstacles concerning disease manage-
ment, such as treatment adherence, since untreated patients
play an important role in the transmission and spread of M.
leprae.12;16(5):472–475
In the present study, no signiﬁcant differences were
observed when comparing genders, while other studies have
found a higher frequency of disease incidence in male
patients. When analyzing the education level, 3% of patients
were illiterate and 70% had ﬁnished middle school. Parra9
identiﬁed that 75% of patients had some degree of education,
while 5% were illiterate. These ﬁndings reﬂect the social sta-
tus of individuals affected by this disease, i.e., the observed
results may reﬂect the social exclusion of this population. The
predominant age group in this study was 42 to 50 years old,
which is similar to that observed by Hinrichsen et al.10 and
Barro.11
An epidemiological study by Resende et al.12 revealed
the prevalence of cases with clinical classiﬁcation of multi-
bacillary type, similarly to what was observed in this study,
suggesting a rather late diagnosis. BCG scar was found
in 70% of the interviewed patients (p<0.001). Similar data
were found in the study of Ferreira,13 who reported the
presence of scar in 76% of their cases. Studies by Zodpey
et al.14 showed that BCG vaccine was effective against lep-
rosy, presenting levels of protection ranging from 36% to
90%.
78.6% of the patients were from Fortaleza, similar to what
was observed by Gomes et al.15 Considering that the Centro de
Referência Nacional em Dermatologia Sanitária Dona Libânia
is located in Fortaleza, most patients are expected to be from
Fortaleza and surroundings.
The two major complaints concerning leprosy ther-
apy were those related to drug reactions and treatment
durations. These complaints may have inﬂuenced the
Morisky-Green test, which revealed low level adherence
in the interviewed patients. Due to the lack of research
using this scale with leprosy patients, the obtained data
were compared with those of Cunha et al.,16 who used the
same test to analyze treatment adherence in hepatitis C
patients.
Of the 70 diagnosed patients, 53% claimed to have heard
about leprosy before knowing they were sick. Conversely,
Resende et al.12 observed that 83.3% of leprosy patients
did not know about the disease before acquiring it, and
that 50% of them, even after receiving care, were still
unaware of the disease, including its clinical-epidemiological
aspects.
Interestingly, this study shows that patients claiming
to know the disease and its treatment were actually
not aware of the principles of leprosy therapy based
on the Morisky-Green test results, which evidenced low
level treatment adherence. Identifying the main reasons
why patients do not properly adhere with treatment
will help health professionals to ﬁnd rapid and efﬁcient
solutions to solve this important issue. Additionally, partic-
ipation of a multidisciplinary staff is important to promote
knowledge of this disease, which may help overcoming
problems concerning treatment failure and disease dissem-
ination.Conﬂict of interest
All authors declare to have no conﬂict of interest.
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